ArticleNpj imaging2026
A single-step radiolabeling strategy for PET, SPECT, and therapeutic radionuclides using nanoparticles as a universal chelator.
Article in Npj imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Innovative Designs of Multimodal Imaging Based on Radionuclide, Quantum, and Cargo-Loaded Nanoplatform Emitters Towards Enhanced Energy-Matter Interactions for Photonics and Bioassays.Materials (Basel, Switzerland) · 2026Review
- Advances in Nuclear Medicine Diagnostics: The Promise of Radiolabeled Dendrimers.Molecules (Basel, Switzerland) · 2026Review
- Selective Chemistry Enables Simultaneous ImmunoPET and Radioimmunotherapy with a Dual-Labeled Probe.JACS Au · 2026Article
- Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Radiopharmaceuticals that combine diagnostic and therapeutic isotopes are at the forefront of novel cancer treatments. A crucial element is the method of attaching radioisotopes to biomolecules using chelator-based techniques that are widely used clinically. Selection from available chelators is essential because this choice influences the physicochemical and biological characteristics of the final radiopharmaceutical. Numerous chelators exist because none fulfill all ideal conditions: rapid and complete binding to radiometals at low concentrations and with metallic impurities, high thermodynamic and kinetic stability in vivo, easy bioconjugation, and, key for this work, achieving these for many radiometals from the growing list of medical isotopes. We demonstrate how nanotechnology may change this. Ten nano-radiotracers were synthesized, incorporating radiometals such as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.